Skip to content
Apr 05 2019

Small Cap Biotech Getting Pricey Again

  • Apr 5, 2019

In May 2015, we warned about rich valuations for small cap Biotech stocks and looked at various ways to evaluate those companies, as the majority have no approved drugs on the market, thus no revenue; therefore, valuing these companies using the conventional methodology is problematic.

Login

For full access, please enter your credentials.
Remember Me

About The Author

Jun Zhu / Sr. Research Analyst & Co-Portfolio Manager